The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early progression of disease (POD24) as survival predictor in MALT lymphoma.
 
Annarita Conconi
Consulting or Advisory Role - Takeda
Travel, Accommodations, Expenses - Celgene; Janssen; Roche
 
Catherine Thieblemont
Honoraria - Abbvie; Bayer; Celgene; Incyte; Janssen; Roche
Research Funding - Roche
 
Luciano Cascione
Travel, Accommodations, Expenses - HTG Molecular Diagnostics
 
Valter Torri
No Relationships to Disclose
 
Barbara Kiesewetter
Honoraria - Celgene; Novartis
 
Gloria Margiotta-Casaluci
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Gianluca Gaidano
Honoraria - Abbvie; GlaxoSmithKline; Janssen; MorphoSys; Roche; Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Novartis; Roche
Speakers' Bureau - Abbvie; Abbvie; Abbvie; Gilead Sciences; Janssen
Travel, Accommodations, Expenses - Amgen; Janssen
 
Markus Raderer
No Relationships to Disclose
 
Franco Cavalli
Research Funding - Janssen
Travel, Accommodations, Expenses - MSD Oncology
 
Armando Lopez-Guillermo
Consulting or Advisory Role - Celgene; Incyte; Janssen; Kite/Gilead; Roche; Takeda
Research Funding - Celgene; Gilead Sciences; Roche
Travel, Accommodations, Expenses - Roche
 
Peter W. M. Johnson
Honoraria - Bristol-Myers Squibb; Celgene; Genmab; Incyte; Kite, a Gilead company; MorphoSys; Novartis; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Epizyme; Janssen
Research Funding - Epizyme (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Combined use of Fc gamma RIIb (CD32b) and CD20 - specific antibodies. WO Patent, PCT/GB2011/051572; EU11760819.0
 
Emanuele Zucca
No Relationships to Disclose